vs
Aurinia Pharmaceuticals Inc.(AUPH)とRepay Holdings Corp(RPAY)の財務データ比較。上の社名をクリックして会社を切り替えられます
Repay Holdings Corpの直近四半期売上が大きい($78.6M vs $77.1M、Aurinia Pharmaceuticals Inc.の約1.0倍)。Aurinia Pharmaceuticals Inc.の純利益率が高く(273.4% vs -178.3%、差は451.6%)。Aurinia Pharmaceuticals Inc.の前年同期比売上増加率が高い(28.8% vs 0.4%)。過去8四半期でAurinia Pharmaceuticals Inc.の売上複合成長率が高い(23.8% vs -1.3%)
オーリニアファーマシューティカルズは後期臨床段階のバイオ医薬品企業で、自己免疫疾患や腎臓疾患向け標的療法の開発・販売を事業の軸としています。主な承認製品に成人活動性ループス腎炎治療薬のルプキニスがあり、北米・欧州市場を中心に事業を展開しています。
Repay Holdings Corpは北米を主要市場とする決済テクノロジー企業で、小売、医療、自動車サービス、電子商取引などの業種の企業向けに、クレジット・デビットカード決済処理、ACH送金、POSシステム連携を含む統合決済ソリューションを提供し、顧客の業務効率化を支援しています。
AUPH vs RPAY — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | ||
|---|---|---|
| 売上 | $77.1M | $78.6M |
| 純利益 | $210.8M | $-140.1M |
| 粗利率 | 88.6% | 74.2% |
| 営業利益率 | 43.1% | -182.2% |
| 純利益率 | 273.4% | -178.3% |
| 売上前年比 | 28.8% | 0.4% |
| 純利益前年比 | 14651.2% | -3304.1% |
| EPS(希薄化後) | $1.52 | $-1.68 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $77.1M | $78.6M | ||
| Q3 25 | $73.5M | $77.7M | ||
| Q2 25 | $70.0M | $75.6M | ||
| Q1 25 | $62.5M | $77.3M | ||
| Q4 24 | $59.9M | $78.3M | ||
| Q3 24 | $67.8M | $79.1M | ||
| Q2 24 | $57.2M | $74.9M | ||
| Q1 24 | $50.3M | $80.7M |
| Q4 25 | $210.8M | $-140.1M | ||
| Q3 25 | $31.6M | $-6.4M | ||
| Q2 25 | $21.5M | $-102.3M | ||
| Q1 25 | $23.3M | $-7.9M | ||
| Q4 24 | $1.4M | $-4.1M | ||
| Q3 24 | $14.3M | $3.2M | ||
| Q2 24 | $722.0K | $-4.1M | ||
| Q1 24 | $-10.7M | $-5.2M |
| Q4 25 | 88.6% | 74.2% | ||
| Q3 25 | 88.9% | 74.4% | ||
| Q2 25 | 89.8% | 75.7% | ||
| Q1 25 | 86.3% | 75.9% | ||
| Q4 24 | 90.7% | 76.3% | ||
| Q3 24 | 91.1% | 77.8% | ||
| Q2 24 | 84.4% | 78.2% | ||
| Q1 24 | 84.6% | 76.2% |
| Q4 25 | 43.1% | -182.2% | ||
| Q3 25 | 40.5% | -3.9% | ||
| Q2 25 | 28.7% | -138.7% | ||
| Q1 25 | 35.0% | -4.7% | ||
| Q4 24 | -2.8% | -1.5% | ||
| Q3 24 | 17.3% | -0.9% | ||
| Q2 24 | -2.6% | -4.6% | ||
| Q1 24 | -26.3% | -3.1% |
| Q4 25 | 273.4% | -178.3% | ||
| Q3 25 | 42.9% | -8.3% | ||
| Q2 25 | 30.7% | -135.2% | ||
| Q1 25 | 37.4% | -10.3% | ||
| Q4 24 | 2.4% | -5.3% | ||
| Q3 24 | 21.2% | 4.1% | ||
| Q2 24 | 1.3% | -5.4% | ||
| Q1 24 | -21.4% | -6.5% |
| Q4 25 | $1.52 | $-1.68 | ||
| Q3 25 | $0.23 | $-0.08 | ||
| Q2 25 | $0.16 | $-1.15 | ||
| Q1 25 | $0.16 | $-0.09 | ||
| Q4 24 | $0.00 | $-0.04 | ||
| Q3 24 | $0.10 | $0.03 | ||
| Q2 24 | $0.01 | $-0.04 | ||
| Q1 24 | $-0.07 | $-0.06 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $80.2M | $115.7M |
| 総負債低いほど良い | — | $280.1M |
| 株主資本純資産 | $581.3M | $484.4M |
| 総資産 | $751.6M | $1.2B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.58× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $80.2M | $115.7M | ||
| Q3 25 | $72.9M | $95.7M | ||
| Q2 25 | $52.9M | $162.6M | ||
| Q1 25 | $66.1M | $165.5M | ||
| Q4 24 | $83.4M | $189.5M | ||
| Q3 24 | $36.6M | $168.7M | ||
| Q2 24 | $33.3M | $147.1M | ||
| Q1 24 | $63.9M | $128.3M |
| Q4 25 | — | $280.1M | ||
| Q3 25 | — | $279.5M | ||
| Q2 25 | — | $279.0M | ||
| Q1 25 | — | $497.6M | ||
| Q4 24 | — | $496.8M | ||
| Q3 24 | — | $496.2M | ||
| Q2 24 | — | $435.6M | ||
| Q1 24 | — | $434.9M |
| Q4 25 | $581.3M | $484.4M | ||
| Q3 25 | $365.8M | $616.9M | ||
| Q2 25 | $335.3M | $633.7M | ||
| Q1 25 | $350.2M | $755.7M | ||
| Q4 24 | $377.5M | $761.3M | ||
| Q3 24 | $388.0M | $754.7M | ||
| Q2 24 | $364.6M | $815.4M | ||
| Q1 24 | $359.5M | $813.8M |
| Q4 25 | $751.6M | $1.2B | ||
| Q3 25 | $527.5M | $1.3B | ||
| Q2 25 | $502.6M | $1.4B | ||
| Q1 25 | $504.9M | $1.5B | ||
| Q4 24 | $550.6M | $1.6B | ||
| Q3 24 | $549.4M | $1.6B | ||
| Q2 24 | $523.5M | $1.5B | ||
| Q1 24 | $516.6M | $1.5B |
| Q4 25 | — | 0.58× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 0.65× | ||
| Q3 24 | — | 0.66× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 0.53× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $45.7M | $23.3M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $23.2M |
| FCFマージンFCF / 売上 | — | 29.6% |
| 設備投資強度設備投資 / 売上 | — | 0.1% |
| キャッシュ転換率営業CF / 純利益 | 0.22× | — |
| 直近12ヶ月FCF直近4四半期 | — | $90.7M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $45.7M | $23.3M | ||
| Q3 25 | $44.4M | $32.2M | ||
| Q2 25 | $44.2M | $33.1M | ||
| Q1 25 | $1.3M | $2.5M | ||
| Q4 24 | $30.1M | $34.3M | ||
| Q3 24 | $17.0M | $60.1M | ||
| Q2 24 | $15.8M | $31.0M | ||
| Q1 24 | $-18.6M | $24.8M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | — | $32.1M | ||
| Q2 25 | — | $33.0M | ||
| Q1 25 | — | $2.4M | ||
| Q4 24 | — | $34.0M | ||
| Q3 24 | — | $59.8M | ||
| Q2 24 | — | $30.5M | ||
| Q1 24 | — | $24.7M |
| Q4 25 | — | 29.6% | ||
| Q3 25 | — | 41.3% | ||
| Q2 25 | — | 43.6% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 43.5% | ||
| Q3 24 | — | 75.6% | ||
| Q2 24 | — | 40.7% | ||
| Q1 24 | — | 30.6% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.6% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | 0.22× | — | ||
| Q3 25 | 1.41× | — | ||
| Q2 25 | 2.06× | — | ||
| Q1 25 | 0.06× | — | ||
| Q4 24 | 21.07× | — | ||
| Q3 24 | 1.19× | 18.52× | ||
| Q2 24 | 21.94× | — | ||
| Q1 24 | — | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AUPH
| Products | $74.2M | 96% |
| License Collaboration And Royalty Revenue | $2.9M | 4% |
RPAY
| Sales Channel Directly To Consumer | $69.4M | 88% |
| Other | $6.8M | 9% |
| Sales Channel Through Intermediary | $2.3M | 3% |